Our client, Sanofi-Aventis, has obtained FDA approval for its new atrial fibrillation/atrial flutter treatment, MULTAQ.  The product is expected to be available later this summer.

Congratulations to Sanofi-Aventis!

This entry was posted on Friday, July 3rd, 2009 at 3:15 pm and is filed under Trademarks. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.